REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Stack Library

Browse community-submitted peptide stacks with dosing protocols, goals, and research notes.

No stacks yet

Be the first to submit a stack below.

Sign in to submit your own stack.

Sign in to contribute

All tools are for research purposes only. Peptide Contacts does not provide medical advice. Consult a qualified healthcare professional before making any decisions based on the information provided here.